ArticleBone marrow transplantation2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.
Aditi Saha et al.PubMed ↗Publisher ↗
No numbers read from the abstract.